NICE publishes final draft guidelines backing GSK’s Strimvelis
admin 3rd January 2018 Uncategorised 0Cost regulators for NHS funded therapies in England and Wales have now published final draft guidance approving GlaxoSmithKline’s gene therapy Strimvelis for an ultra-rare immune deficiency condition commonly referred to as bubble baby syndrome.
More: NICE publishes final draft guidelines backing GSK’s Strimvelis
Source: News